Description
A bioactive sphingolipid; inhibits IL-4 production by 53.84% in EL4 T cells (10 μM); reduces the growth of human papillomavirus type 16-associated tumors in mice; reduces natural killer T cell activity, delays the onset of proteinuria, and improves survival in a mouse model of systemic lupus
Formal name: N-[(1S,2R,3E)-1-[(β-D-galactopyranosyloxy)methyl]-2-hydroxy-3-heptadecen-1-yl]-dodecanamide
Synonyms: Galactosylceramide (d18:1/12:0)|GalCer(d18:1/12:0)|N-dodecanoyl-β-D-Galactosylceramide
Molecular weight: 643.9
CAS: 41613-14-3
Purity: ≥95%
Formulation: A solid
Product Type|Biochemicals|Lipids|Sphingolipids||Research Area|Cancer||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Immunology & Inflammation|Autoimmunity|Lupus||Research Area|Lipid Biochemistry|Sphingolipids